ProBioGen
Skip navigation
  • Services
  • Innovative Technologies
  • Company
  • News & Events
  • Careers
  • Contact
  • Search
 
Skip navigation
  • Services
    • GMP Production Cell Lines
    • Process Development
    • Virus Production Development
    • GMP Manufacturing
    • Biosimilars & Biobetters
    • Analytics/Bioassays
    • Quality Management
  • Innovative Technologies
    • Genetic Glyco-Engineering/ ADCC (GlymaxX®)
    • Virus Production Cell Lines
    • Viral Vector Technologies
    • DirectedLuckTM Transposase with Epigenetic Targeting
    • Immunogenicity/-function Testing (Human Artificial
      Lymph Node)
    • Productivity Increase
  • Company
  • News & Events
    • Press Releases
    • Publications
    • Events
  • Careers
    • Open Positions
    • Unsolicited Applications
    • Applicant Login
    • FAQ
    • Contact & Directions
  • Contact
    • General Contact
    • Legal Notice
    • Disclaimer
    • Data Protection
  • Search
 

Press Releases

01 Sep 2005

ProBioGen successfully completes development project by delivering recombinant Solulin to PAION for pre-clinical testing

read more ProBioGen successfully completes development project by delivering recombinant Solulin to PAION for pre-clinical testing

  • download PDF

Page 8 of 8

  • « First
  • Previous
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8

News & Events

Skip navigation
  • Press Releases
  • Publications
  • Events
 

Most Frequently Read News

ProBioGen licenses GlymaxX® Technology to AbbVie

read more ProBioGen licenses GlymaxX® Technology to AbbVie

Asahi Kasei Pharma contracts ProBioGen for the Advancement of their Biologics Pipeline

read more Asahi Kasei Pharma contracts ProBioGen for the Advancement of their Biologics Pipeline

ProBioGen AG appoints Dr. Lutz Hilbrich as new Chief Executive Officer - Dr. Wieland Wolf retires

read more ProBioGen AG appoints Dr. Lutz Hilbrich as new Chief Executive Officer - Dr. Wieland Wolf retires

ProBioGen and Lava Therapeutics Sign Cell Line Development and GMP Manufacturing Agreement for Novel Bispecific Molecule

read more ProBioGen and Lava Therapeutics Sign Cell Line Development and GMP Manufacturing Agreement for Novel Bispecific Molecule

ProBioGen inks next Commercial GlymaxX® License with Roche

read more ProBioGen inks next Commercial GlymaxX® License with Roche

ProBioGen News

Join our news and always be up-to-date.

  Sign up

ProBioGen AG

  • Headquarters
  • Herbert-Bayer-Straße 8
  • 13086 Berlin, Germany
  • Phone: +49 (0) 30 3229 35 100
  • Email: info@probiogen.de
Copyright © 2021 ProBioGen AG
Legal Notice | Disclaimer | Data Protection